1. Ferrari, S., Smeland, S., Mercuri, M., Bertoni, F., Longhi, A., Ruggieri, P., et al. (2005). Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups [Clinical Trial Comparative Study Multicenter Study]. Journal of Clinical Oncology, 23(34), 8845–8852.
2. Ozaki, T., Flege, S., Kevric, M., Lindner, N., Maas, R., Delling, G., et al. (2003). Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group [Multicenter Study Research Support, Non-U.S. Gov’t]. Journal of Clinical Oncology, 21(2), 334–341.
3. Smithey, B. E., Pappo, A. S., & Hill, D. A. (2002). C-kit expression in pediatric solid tumors: a comparative immunohistochemical study [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. The American Journal of Surgical Pathology, 26(4), 486–492.
4. McGary, E. C., Weber, K., Mills, L., Doucet, M., Lewis, V., Lev, D. C., et al. (2002). Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571 [Research Support, U.S. Gov’t, P.H.S.]. Clinical Cancer Research, 8(11), 3584–3591.
5. Kaya, M., Wada, T., Akatsuka, T., Kawaguchi, S., Nagoya, S., Shindoh, M., et al. (2000). Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clinical Cancer Research, 6(2), 572–577.